Curcumin-loaded solid lipid nanoparticles (SLNs) were fabricated using the emulsification-solvent evaporation method. The SLNs exhibited an average particle size of 136.7 ± 8.36 nm, with an entrapment efficiency of 70.83 ± 0.54%. In vitro release studies showed a sustained release profile, with 45.66% of the drug released over 24 hours, indicating prolonged drug delivery compared to curcumin plain gel. In an inflammation model, the formulation demonstrated significant inhibition of edema, with a maximum inhibition of 73.81±0.206% observed after three hours of inflammation induction. Furthermore, when applied 12 hours before carrageenan injection, the formulation exhibited sustained therapeutic action, resulting in 94±0.106% inhibition of edema. Skin irritation studies revealed no significant irritation, suggesting the formulation's safety for topical application. These findings underscore the potential of curcumin-loaded SLNs as an effective strategy for acute pain therapy, offering enhanced stability and sustained therapeutic effects when administered topically